Agilent Technologies announces more than one million bioanalyzer chips sold
Agilent Technologies Inc. announced that it has sold more than one million LabChip(r) chips -- small, analytical devices used with the Agilent 2100 bioanalyzer to perform fast, automated analysis of DNA, RNA, proteins and cells. These chips are based on lab-on-a-chip technology, which relies on the principles of microfluidics to manipulate tiny amounts of liquid within a miniaturized system.
"Scientists recognize the benefits of lab-on-a-chip technology for improving speed, data quality and ease of use," said Tony Owen, liquid phase analysis platform marketing manager for Agilent's Pharmaceutical Analysis business. "They are making extensive use of our technology in their peer-reviewed research, as seen in the more than 1,000 citations for the bioanalyzer in scientific literature."
In collaboration with Caliper Life Sciences, Inc., Agilent introduced the industry's first commercial lab-on-a-chip system, the Agilent 2100 bioanalyzer, in 1999. With more than 2,500 sold, the bioanalyzer has become a valuable tool for genomics, proteomics, biopharmaceutical development and manufacturing, food safety and homeland security. In genomics, the bioanalyzer has become an industry-standard platform for RNA quality assessment in gene expression, polymerase chain reaction and RNA interference experiments.
Other news from the department business & finance
These products might interest you
Kjel- / Dist Line by Büchi
Kjel- and Dist Line - steam distillation and Kjeldahl applications
Maximum accuracy and performance for your steam distillation and Kjeldahl applications
AZURA Purifier + LH 2.1 by KNAUER
Preparative Liquid Chromatography - New platform for more throughput
Save time and improve reproducibility during purification
